Summary: Genmab's partner, Roche has initiated a Phase II study of R1507 for
the treatment of sarcoma.
Copenhagen, Denmark; December 20, 2007 - Genmab A/S (OMX: GEN) announced today
that its partner, Roche has initiated a Phase II clinical study of R1507 for the
treatment of recurrent or refractory sarcoma The R1507 antibody was created by
Genmab under the company's agreement with Roche and initiation of the trial will
trigger a milestone payment to Genmab of USD 500,000.
“R1507 will be the first antibody created by Genmab under our agreement with
Roche to enter Phase II development,” said Lisa N. Drakeman, Ph.D., Chief
Executive Officer of Genmab. “We believe that R1507 may offer an additional
treatment option to sarcoma patients.”
About Sarcoma
Sarcoma is a cancer of the connective tissue including muscle, bone, fat, nerve,
cartilage, blood vessel and deep skin tissue. Due to the wide variety of types
of sarcoma, the disease is often difficult to detect, is often misdiagnosed and
is complex to treat. Sarcoma is a rare type of cancer with US incidence of
approximately 9,000 to 11,000 new cases per year. Of these approximately 8,000
are cases of soft tissue sarcoma and 2,000 are sarcoma of the bone.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 63/2007
###
